Preclinical Studies

Treatment with EHP-102, an investigational cannabinoid-derived medicine, reduced weight loss, preserved motor neurons of the spinal cord, and lowered the abnormal reactivity of astroglial cells in a mouse model of amyotrophic lateral sclerosis (ALS), new research shows. Findings were recently published in the study, “Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an […]

by

Reprinted with the style permission of Dr. Mercola. By Dr. Mercola The marijuana plant comprises bigger than 60 diverse cannabinoids; chemicals the human physique is uniquely equipped to acknowledge to. The 2 most most distinguished ones are cannabidiol (CBD) and tetrahydrocannabinol (THC), the latter of which is the psychoactive ingredient. Cannabinoids engage alongside with your […]

by

Live 2018 The Government of Québec has awarded a total of  $500,000 in funding to McGill University and the Research Institute of the McGill University Health Centre (RI-MUHC). The funding will go to support the completion of two international research and innovation projects, which were selected at the end of the call for projects launched […]

by

<!– Stock News –> August 16, 2018 – By Estela Ashley Fj Capital Management Llc decreased Univest Corp Pa (NASDAQ:UVSP) stake by 67.43% reported in 2018Q2 SEC filing. Fj Capital Management Llc sold 504,700 shares as Univest Corp Pa (NASDAQ:UVSP)’s stock rose 4.40%. The Fj Capital Management Llc holds 243,800 shares with $6.71M value, down […]

by

Montreal – The Government of Québec has awarded a total of  $500,000 in funding to the McGill University and the Research Institute of the McGill University Health Center (RI-MUHC) to support the completion of two international research and innovation projects, which were selected at the end of the call for projects launched in April 2017 […]

by

<!– Market News –> August 11, 2018 – By Rachel Eickhoff Sawgrass Asset Management Llc increased On Assignment (ASGN) stake by 88.41% reported in 2018Q1 SEC filing. Sawgrass Asset Management Llc acquired 15,945 shares as On Assignment (ASGN)’s stock declined 0.23%. The Sawgrass Asset Management Llc holds 33,980 shares with $2.78 million value, up from […]

by

<!– Trending Stock News –> August 6, 2018 – By Joe Cepeda Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) had an increase of 29.94% in short interest. NVIV’s SI was 315,100 shares in August as released by FINRA. Its up 29.94% from 242,500 shares previously. With 329,200 avg volume, 1 days are for Invivo Therapeutics Holdings Corp […]

by

<!– Trending Stock News –> August 2, 2018 – By Carolyn Hewitt Minerals Technologies Inc (NYSE:MTX) is expected to pay $0.05 on Sep 6, 2018. (NYSE:MTX) shareholders before Aug 23, 2018 will receive the $0.05 dividend. Minerals Technologies Inc’s current price of $74.65 translates into 0.07% yield. Minerals Technologies Inc’s dividend has Aug 24, 2018 […]

by

<!– Market News –> July 24, 2018 – By Margaret Guttierez Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) had an increase of 29.94% in short interest. NVIV’s SI was 315,100 shares in July as released by FINRA. Its up 29.94% from 242,500 shares previously. With 329,200 avg volume, 1 days are for Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s […]

<!– Market News –> July 24, 2018 – By Margaret Guttierez Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) had an increase of 29.94% in short interest. NVIV’s SI was 315,100 shares in July as released by FINRA. Its up 29.94% from 242,500 shares previously. With 329,200 avg volume, 1 days are for Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s […]

<!– Market News –> July 15, 2018 – By Joe Cepeda Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) had an increase of 29.94% in short interest. NVIV’s SI was 315,100 shares in July as released by FINRA. Its up 29.94% from 242,500 shares previously. With 329,200 avg volume, 1 days are for Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s […]

Emerald Health Pharmaceuticals’ lead cannabinoid-derived treatment candidate, EHP-101, has shown potential to prevent skin and lung tissue scaring in a mouse model of systemic sclerosis, the company reports. Emerald also claims that EHP-101’s therapeutic activity is similar or superior to that seen in ajulemic acid, also known as lenabasum — a potential treatment being developed by Corbus Pharmaceuticals […]

Emerald Health Pharmaceuticals’ lead cannabinoid-derived treatment candidate, EHP-101, has shown potential to prevent skin and lung tissue scaring in a mouse model of systemic sclerosis, the company reports. Emerald also claims that EHP-101’s therapeutic activity is similar or superior to that seen in ajulemic acid, also known as lenabasum — a potential treatment being developed by Corbus Pharmaceuticals […]